ArticleFrontiers in oncology2025
Atrial arrhythmias related to antitumor treatment in patients with coronary heart disease and malignant tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This study investigated the occurrence of arrhythmias in patients with malignant tumors and coronary heart disease (CHD) during antitumor drug treatment. Methods: 109 patients with malignant tumors undergoing antitumor treatment at Zhejiang Hospital from January 2023 to January 2024 were analyzed. All patients underwent 12-lead ECG before and after each chemotherapy cycle. The primary endpoint was the occurrence of new arrhythmias recorded through ECG. Univariate and multivariate logistic regression analysis were performed to recognize the risk factors. Results: Atrial arrhythmias occurred in 13 cases (11.93%). The incidence of atrial arrhythmias was significantly higher in the CHD group compared to the non-CHD group (27.27% vs 1.54%; P < 0.001). Multivariate logistic regression analysis indicated that smoking (P = 0.009), ischemic heart disease (P = 0.006), and left ventricular ejection fraction < 50% (P = 0.014) increased the risk of developing arrhythmias after antitumor treatment. Conclusion: Atrial arrhythmias are more common in cancer patients with CHD when undergoing antitumor treatment. A history of smoking, ischemic heart disease, and reduced left ventricular ejection fraction increases the risk of atrial arrhythmias after antitumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.